HJHoward M. Johnson

Howard M. Johnson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Howard M. Johnson has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Editorial: SOCS: regulation of the immune system at a whole new level

    by Sandra E. Nicholson, Chulbul M. Ahmed, Karen Doggett, Daniela Marasco, Howard M. Johnson

    Immune checkpoints orchestrate a complex regulatory network, tasked with keeping the immune system in check to avoid autoimmune and inflammatory diseases. The field is dominated by the development of new checkpoint blockers to treat cancer and infectious diseases, following the success of antibody therapies targeting programmed cell death 1 (PD-1), its ligand PD-L1 or cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) that have revolutionized cancer treatment. Regulatory T cells (Tregs) and members of a protein family of intracellular regulators called Suppressors of cytokine signaling (CIS, SOCS1, SOCS2 and SOCS3) play central roles to limit the immune response. SOCS1 is a key checkpoint in the immune response to cancer and infection, SOCS3 in various inflammatory diseases, and together they allow crosstalk among cytokines in non-immune and immune cells. CIS (CISH gene) is a critical checkpoint in Natural killer (NK) and T cell control of cancer, while SOCS2 has been reported to have roles in controlling allergy and cancer, including acute myeloid leukemia. Many of these regulatory players are interconnected and interdependent. For example, SOCS1 was shown to stabilize Foxp3+ Treg peripheral cells. There is also evidence that SOCS1 can regulate other checkpoints such as PD-L1, via inhibition of interferon gamma (IFN) signaling. Thus, manipulation of SOCS activity or levels could influence other checkpoint factors, and/or synergize with current immune checkpoint blockers. Given that the SOCS proteins are intracellular regulators, the challenge is to positively and negatively regulate these molecules in an informative way with potential for therapeutic translation.The interest in CIS and SOCS1 as powerful immune checkpoint modulators, is evidenced by an active Phase I/II clinical trial using autologous CISH-deleted tumor infiltrating lymphocytes (TILs; NCT04426669) in gastrointestinal cancer, and recruitment for two new trials using SOCS1deleted TILs (NCT06237881/NCT06237881). Despite this, there appears to be a widespread lack of awareness that SOCS are key immune checkpoints. This was reflected in a recent call for innovative immune checkpoint inhibitors, which neglected to mention the SOCS system. This may be because unlike PD-1 and CTLA-4, which can be targeted by antibodies, regulation of SOCS activity presents a unique challenge due to their intracellular location, and the inherent difficulty of targeting the conserved SH2 or SOCS box function. Contrary to this perception, there are multiple strategies, including gene editing, anti-sense oligonucleotides, microRNAs and intracellular antibodies, that could be used to manipulate SOCS function.This Research Topic includes 8 reviews and one primary research article that explore various cytokine and SOCS-related disorders, examining different approaches to regulate SOCS protein activity. However, these papers are just the tip of the iceberg. The recent development of a chemical SOCS2-SH2 inhibitor (this Topic; Lynch et al.) offers hope that the SOCS-SH2 domain is not as intractable as previously thought. Effective SOCS1 and SOCS3 peptidomimetic agonists and antagonists have been developed with potential for treatment of viral and bacterial infections, cancer, autoimmune and inflammatory diseases such as uveitis, as well as the cellular dysregulation associated with type 2 diabetes. In particular, a cell penetrating peptide mimicking the SOCS1/3 kinase inhibitory region (KIR) has potential for treatment of several blinding diseases including uveitis, diabetic retinopathy, glaucoma and macular degeneration (this Topic; Stafford et al., Ahmed et al., Cugudda et al., Johnson & Ahmed).Haploinsufficiency for loss-of-function SOCS1 variants is associated with inflammatory autoimmune diseases such as rheumatoid arthritis, SLE and psoriasis, while in mice, SOCS1 restraint of inflammatory signaling is critical for post-natal survival (this Topic: Bidgood et al.; Korholz et al.). Specifically, SOCS1 knockout mice, although born viable, only survive for a few weeks as SOCS1 is a key regulator of the cytokine IFN, which in the absence of SOCS1, drives a fatal systemic inflammatory disease. Reconstitution of SOCS1 knockout mice with a SOCS1 mimetic containing the kinase inhibitory region (KIR) together with CD4 + T cells is partially protective; providing some insight into the complex interactions between regulatory factors, including cytokines, immune cells, and SOCS1 that are required for homeostasis regarding the function of SOCS. Importantly, SOCS1 and SOCS3 have been shown to be intrinsic virulence factors, capable of enhancing viral diseases by suppression of type I interferon signaling. A peptide corresponding to the activation loop of JAK2 (residues 1001-1013) has been shown to counteract SOCS1/3 induction, and was similarly found to have broad antiviral activity against a variety of viruses in animal models (this Topic: Ahmed & Johnson).Interestingly, loss of SOCS1 and SOCS3 results in skin inflammation, and has been associated with an increased rate of cancer onset (this Topic: Morelli et al.). SOCS1 in particular can both restrict anti-tumor immunity and act as a tumor suppressor, depending on the cellular and disease context (this Topic: Bidgood et al.; Ilangumaran et al.). SOCS1 has roles in CD4 + and CD8 + T cells, dendritic cells and macrophages that limit anti-tumor immunity. SOCS1 inhibition of IFN-driven MHC-I expression may also increase immune evasion, while paradoxically, SOCS1-associated proteasomal activity may affect antigen processing and presentation, resulting in enhanced immune recognition. The loss of SOCS1 by epigenetic or micro-RNA mediated mechanisms has also resulted in tumor progression in several cancers (this Topic: Korholz et al.).Although this collection of articles has a strong focus on SOCS1, we should not forget the important role of SOCS3 in limiting inflammatory signaling...


  • Open Access

    Disparate viral pandemics from COVID19 to monkeypox and beyond: a simple, effective and universal therapeutic approach hiding in plain sight

    by Howard M. Johnson, Chulbul M. Ahmed

    The field of antiviral therapeutics is fixated on COVID19 and rightly so as the fatalities at the height of the pandemic in the United States were almost 1,000,000 in a twelve month period spanning parts of 2020/2021. A coronavirus called SARS–CoV2 is the causative virus. Development of a vaccine through molecular biology approaches with mRNA as the inducer of virus spike protein has played a major role in driving down mortality and morbidity. Antivirals have been of marginal value in established infections at the level of hospitalization. Thus, the current focus is on early symptomatic infection of about the first five days. The Pfizer drug paxlovid which is composed of nirmatrelvir, a peptidomimetic protease inhibitor of SARS–CoV2 Mpro enzyme, and ritonavir to retard degradation of nirmatrelvir, is the current FDA recommended treatment of early COVID19. There is no evidence of broad antiviral activity of paxlovid against other diverse viruses such as the influenza virus, poxviruses, as well as a host of respiratory viruses. Although type I interferons (IFNs) are effective against SARS–CoV2 in cell cultures and in early COVID19 infections, they have not been broadly recommended as therapeutics for COVID19. We have developed stable peptidomimetics of both types I and II IFNs based on our noncanonical model of IFN signaling involving the C-terminus of the IFNs. We have also identified two members of intracellular checkpoint inhibitors called suppressors of cytokine signaling (SOCS), SOCS1 and SOCS3 (SOCS1/3), and shown that they are virus induced intrinsic virulence proteins with activity against IFN signaling enzymes JAK2 and TYK2. We developed a peptidomimetic antagonist, based on JAK2 activation loop, against SOCS1/3 and showed that it synergizes with the IFN mimetics for potent broad spectrum antiviral activity without the toxicity of intact IFN molecules. IFN mimetics and the SOCS1/3 antagonist should have an advantage over currently used antivirals in terms of safety and potency against a broad spectrum of viruses.


  • Open Access

    SOCS, Intrinsic Virulence Factors, and Treatment of COVID-19

    by Howard M. Johnson, Alfred S. Lewin, Chulbul M. Ahmed

    The suppressor of cytokine signaling (SOCS) family of intracellular checkpoint inhibitors has received little recognition compared to other checkpoint inhibitors. Two members of this family, SOCS1 and SOCS3, are indispensable, since SOCS1 knockout in mice results in neonatal death due to interferon gamma (IFNγ) induced inflammatory disease, and SOCS3 knockout leads to embryonic lethality. We have shown that SOCS1 and SOCS3 (SOCS1/3) function as virus induced intrinsic virulence factors for influenza A virus, EMC virus, herpes simplex virus 1 (HSV-1), and vaccinia virus infections. Other viruses such as pathogenic pig enteric coronavirus and coronavirus induced severe acute respiratory syndrome (SARS) spike protein also induce SOCS virus intrinsic virulence factors. SOCS1/3 exert their viral virulence effect via inhibition of type I and type II interferon (IFN) function. Specifically, the SOCS bind to the activation loop of receptor-associated tyrosine kinases JAK2 and TYK2 through the SOCS kinase inhibitory region (KIR), which inhibits STAT transcription factor activation by the kinases. Activated STATs are required for IFN function. We have developed a small peptide antagonist of SOCS1/3 that blocks SOCS1/3 inhibitory activity and prevents virus pathogenesis. The antagonist, pJAK2(1001-1013), is comprised of the JAK2 activation loop, phosphorylated at tyrosine 1007 with a palmitate for cell penetration. The remarkable thing about SOCS1/3 is that it serves as a broad, simple tool of perhaps most pathogenic viruses to avoid innate host IFN defense. We suggest in this Perspective that SOCS1/3 antagonist is a simple counter measure to SOCS1/3 and should be an effective mechanism as a prophylactic and/or therapeutic against the COVID-19 pandemic that is caused by coronavirus SARS-CoV2.


  • Open Access

    Noncanonical IFN Signaling, Steroids, and STATs: A Probable Role of V-ATPase

    by Howard M. Johnson, Ezra Noon-Song, Chulbul M. Ahmed

    A small group of only seven transcription factors known as STATs (signal transducer and activator of transcription) are considered to be canonical determinants of specific gene activation for a plethora of ligand/receptor systems. The activation of STATs involves a family of four tyrosine kinases called JAK kinases. JAK1 and JAK2 activate STAT1 in the cytoplasm at the heterodimeric gamma interferon (IFNγ) receptor, while JAK1 and TYK2 activate STAT1 and STAT2 at the type I IFN heterodimeric receptor. The same STATs and JAKs are also involved in signaling by functionally different cytokines, growth factors, and hormones. Related to this, IFNγ-activated STAT1 binds to the IFNγ-activated sequence (GAS) element, but so do other STATs that are not involved in IFNγsignaling. Activated JAKs such as JAK2 and TYK2 are also involved in the epigenetics of nucleosome unwrapping for exposure of DNA to transcription. Furthermore, activated JAKs and STATs appear to function coordinately for specific gene activation. These complex events have not been addressed in canonical STAT signaling. Additionally, the function of noncoding enhancer RNAs, including their role in enhancer/promoter interaction is not addressed in the canonical STAT signaling model. In this perspective, we show that JAK/STAT signaling, involving membrane receptors, is essentially a variation of cytoplasmic nuclear receptor signaling. Focusing on IFN signaling, we showed that ligand, IFN receptor, the JAKs, and the STATs all undergo endocytosis and ATP-dependent nuclear translocation to promoters of genes specifically activated by IFNs. We argue here that the vacuolar ATPase (V-ATPase) proton pump probably plays a key role in endosomal membrane crossing by IFNs for receptor cytoplasmic binding. Signaling of nuclear receptors such as those of estrogen and dihydrotestosterone provides templates for making sense of the specificity of gene activation by closely related cytokines, which has implications for lymphocyte phenotypes.


  • Open Access

    A Cell Penetrating Peptide from SOCS-1 Prevents Ocular Damage in Experimental Autoimmune Uveitis

    by Chulbul M. Ahmed, Michael T. Massengill, Cristhian J. Ildefonso, Howard M. Johnson, Alfred S. Lewin

    We describe an immunosuppressive peptide corresponding to the kinase inhibitory region (KIR) of the intracellular checkpoint protein suppressor of cytokine signaling 1 (SOCS-1) that binds to the phospho-tyrosine containing regions of the tyrosine kinases JAK2 and TYK2 and the adaptor protein MAL, and thereby inhibits signaling downstream from these signaling mediators. The peptide, SOCS1-KIR, is thus capable of downregulating overactive JAK/STAT or NF-kB signaling in somatic cells, including those in many compartments of the eye. Attachment of poly-arginine to this peptide (R9-SOCS1-KIR) allows it to penetrate the plasma membrane in aqueous media. R9-SOCS1-KIR was tested in ARPE-19 cells and was found to attenuate mediators of inflammation by blocking the inflammatory effects of IFNγ, TNFα, or IL-17A. R9-SOCS1-KIR also protected against TNFα or IL-17A mediated damage to the barrier properties of ARPE-19 cells, as evidenced by immunostaining with the tight junction protein, zona occludin 1 (ZO-1), and measurement of transepithelial electrical resistance (TEER). Experimental autoimmune uveitis (EAU) was generated in B10.RIII mice using a peptide of interphotoreceptor retinal binding protein (IRBP 161-180 ) as immunogen. Topical administration of R9-SOCS1-KIR protected ocular structure and function as seen by fundoscopy, optical coherence tomography (OCT), and electroretinography (ERG). The ability R9-SOCS1-KIR to suppress ocular inflammation and preserve barrier properties of retinal pigment epithelium makes it a potential candidate for aqueous treatment of autoimmune uveitis. Highlights: peptide corresponding to the kinase inhibitory region of SOCS-1 linked to poly-arginine (R9-SOCS1-KIR) and its inactive control peptide were chemically synthesized. R9-SOCS1-KIR attenuated pro-inflammatory effects of IFNγ, TNFα, and IL-17 in ARPE-19 cells, thus showing a simultaneous inhibition Th1 and Th17 cell functions. Damage to barrier properties of ARPE-19 cells caused by TNFα or IL-17 was prevented in the presence of R9-SOCS1-KIR. Topical administration of R9-SOCS1-KIR prevented ocular damage in a mouse model of experimental autoimmune uveitis.

  • Open Access

    Editorial: The Dynamic Role of Suppressor of Cytokine Signaling Proteins in the Regulation of Immune and Autoimmune Responses

    by Howard M. Johnson, Joseph Larkin

    Editorial: The Dynamic Role of Suppressor of Cytokine Signaling Proteins in the Regulation of Immune and Autoimmune Responses


  • Open Access

    Noncanonical IFN Signaling: Mechanistic Linkage of Genetic and Epigenetic Events

    by Howard M. Johnson, Chulbul M. Ahmed

    The canonical model of cytokine signaling via the JAK/STAT pathway dominates our view of signal transduction but provides no insight into the significance of the simultaneous presence of activated JAKs and STATs in the nucleus of cells treated with cytokines. Such a mechanistic shortcoming challenges the usefulness of the model in its present form. Focusing on the interferon (IFN) cytokines, we have developed a noncanonical model of IFN signaling that naturally connects activated JAKs and STATs at or near response elements of genes that are activated by the IFNs. Specifically, cells treated with IFNγshowed association of activated STAT1αand JAK2 at the GAS element of genes activated by IFNγ. For IFNαtreated cells, the association involved activated STAT1αand TYK2 JAK kinase at the ISRE promoter. The power of the noncanonical model is that it provides mechanistic insight into specific gene activation at the level of the associated epigenetics, akin to that of steroid/steroid receptor signaling.


  • Open Access

    SOCS1 Mimetics and Antagonists: A Complementary Approach to Positive and Negative Regulation of Immune Function

    by Chulbul M. I. Ahmed, Joseph Larkin, Howard M. Johnson

    Suppressors of cytokine signaling (SOCS) are inducible intracellular proteins that play essential regulatory roles in both immune and non-immune function. Of the eight known members, SOCS1 and SOCS3 in conjunction with regulatory T cells play key roles in regulation of the immune system. Molecular tools such as gene transfections and siRNA have played a major role in our functional understanding of the SOCS proteins where a key functional domain of 12 amino acid residues called the kinase inhibitory region (KIR) has been identified on SOCS1 and SOCS3. KIR plays a key role in inhibition of the JAK2 tyrosine kinase which in turn plays a key role in cytokine signaling. A peptide corresponding to KIR (SOCS1-KIR) bound to the activation loop of JAK2 and inhibited tyrosine phosphorylation of STAT1α transcription factor by JAK2. Cell internalized SOCS1-KIR is a potent therapeutic in the experimental allergic encephalomyelitis (EAE) mouse model of multiple sclerosis and showed promise in a psoriasis model and a model of diabetes associated cardiovascular disease. By contrast, a peptide, pJAK2(1001-1013), that corresponds to the activation loop of JAK2 is a SOCS1 antagonist. The antagonist enhanced innate and adaptive immune response against a broad range of viruses including herpes simplex virus, vaccinia virus, and an EMC picornavirus. SOCS mimetics and antagonists are thus potential therapeutics for negative and positive regulation of the immune system.


  • Open Access

    Gamma Interferon: From Antimicrobial Activity to Immune Regulation

    by Howard M. Johnson

    Gamma Interferon: From Antimicrobial Activity to Immune Regulation


  • Short Peptide Type I Interferon Mimetics: Therapeutics for Experimental Allergic Encephalomyelitis, Melanoma, and Viral Infections

    by Chulbul M. Ahmed, Howard M. Johnson

    The classical canonical model of interferon (IFN) signaling focuses solely on the activation of STAT transcription factors, which limits the model in terms of specific gene activation, associated epigenetic events, and IFN mimetic development. Accordingly, we have developed a noncanonical model of IFN signaling and report the development of short type I IFN peptide mimetic peptides based on the model. The mimetics, human IFNα1(152–189), human IFNβ(150–187), and ovine IFNτ(156–195) are derived from the C-terminus of the parent IFNs and function intracellularly based on the noncanonical model. Vaccinia virus produces a decoy IFN receptor (B18R) that inhibits type I IFN, but the IFN mimetics bypass B18R for effective antiviral activity. By contrast, both parent IFNs and mimetics inhibited vesicular stomatitis virus. The mimetics also possessed anti-tumor activity against murine melanoma B16 tumor cells in culture and in mice, including synergizing with suppressor of cytokine signaling 1 antagonist. Finally, the mimetics were potent therapeutics against experimental allergic encephalomyelitis, a mouse model of multiple sclerosis. The mimetics lack toxic side effects of the parent IFNs and, thus, are a potent therapeutic replacement of IFNs as therapeutics.